Stocktwits on MSN
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum
The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference. ・CEO Angelos ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...
In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results